Business
Viridian Therapeutics Prepares for Transformational 2026
WALTHAM, Mass., January 06, 2026--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing ...
About this update from Viridian Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/8ec2aa52356327b225b55f0e6edef4a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lpQ5.eR1Di3CBh4o7iZI6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8ec2aa52356327b225b55f0e6edef4a5","width":960,"height":240},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FFyhI8TsNyeS1w.igzgFmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8ec2aa52356327b225b55f0e6edef4a5","width":1200,"height":300}},"lazy":false},{"type":"text","content":"- Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track -","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"- Topline phase 3 results for subcutaneous elegrobart (VRDN-003) on track for Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 for active and chronic TED, respectively -","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"- IND submitted for half-life extended FcRn-inhibitor, VRDN-008; healthy volunteer (HV) data expected in 2H 2026 -","length":114,"tagName":"p","attribs":{}},{"type":"text","content":"- Unveiling new program targeting thyroid-stimulating hormone receptor (TSHR); IND expected Q4 2026 -","length":101,"tagName":"p","attribs":{}},{"type":"text","content":"- Cash position of approximately $888 million as of October 31, 2025 -","length":70,"tagName":"p","attribs":{}},{"type":"text","content":"- Company expects its current business plans to be funded through profitability -","length":81,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., January 06, 2026--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company’s key priorities and anticipated catalysts for 2026.","length":319,"tagName":"p"},{"type":"text","content":""Following another year of strong execution across our portfolio, we enter 2026 positioned for meaningful value-creation and progress," s...